- Home
- ALLE vs EXAS Comparison
ALLE vs EXAS Comparison
Compare ALLE & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLE
- EXAS
- Stock Information
- Founded
- ALLE 2013
- EXAS 1995
- Country
- ALLE Ireland
- EXAS United States
- Employees
- ALLE N/A
- EXAS N/A
- Industry
- ALLE Diversified Commercial Services
- EXAS Medical Specialities
- Sector
- ALLE Consumer Discretionary
- EXAS Health Care
- Exchange
- ALLE Nasdaq
- EXAS Nasdaq
- Market Cap
- ALLE 11.9B
- EXAS 10.7B
- IPO Year
- ALLE N/A
- EXAS N/A
- Fundamental
- Price
- ALLE $148.11
- EXAS $53.36
- Analyst Decision
- ALLE Hold
- EXAS Strong Buy
- Analyst Count
- ALLE 7
- EXAS 20
- Target Price
- ALLE $144.14
- EXAS $70.16
- AVG Volume (30 Days)
- ALLE 821.8K
- EXAS 2.8M
- Earning Date
- ALLE 07-23-2025
- EXAS 07-30-2025
- Dividend Yield
- ALLE 1.38%
- EXAS N/A
- EPS Growth
- ALLE 16.19
- EXAS N/A
- EPS
- ALLE 7.12
- EXAS N/A
- Revenue
- ALLE $3,820,200,000.00
- EXAS $2,828,128,000.00
- Revenue This Year
- ALLE $6.09
- EXAS $14.58
- Revenue Next Year
- ALLE $4.60
- EXAS $12.75
- P/E Ratio
- ALLE $20.79
- EXAS N/A
- Revenue Growth
- ALLE 5.48
- EXAS 11.57
- 52 Week Low
- ALLE $113.27
- EXAS $39.97
- 52 Week High
- ALLE $156.10
- EXAS $72.83
- Technical
- Relative Strength Index (RSI)
- ALLE 68.78
- EXAS 49.61
- Support Level
- ALLE $142.64
- EXAS $52.60
- Resistance Level
- ALLE $148.74
- EXAS $55.09
- Average True Range (ATR)
- ALLE 2.43
- EXAS 2.09
- MACD
- ALLE 0.90
- EXAS -0.01
- Stochastic Oscillator
- ALLE 91.97
- EXAS 44.73
About ALLE Allegion plc
Allegion is a global security products company with a portfolio of leading brands such as Schlage, Von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2024, Allegion generated over 75% of sales in the United States. The company primarily competes with Sweden-based Assa Abloy, Switzerland-based Dormakaba, and US-based Fortune Brands Innovations.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.